IP Verse

Immunostimulation By Chemically Modified Rna - EP2216028

The patent EP2216028 was granted to Curevac on Dec 6, 2017. The application was originally filed on Jul 3, 2003 under application number EP10005375A. The patent is currently recorded with a legal status of "Revoked".

EP2216028

CUREVAC
Application Number
EP10005375A
Filing Date
Jul 3, 2003
Status
Revoked
May 29, 2020
Grant Date
Dec 6, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ETHERNA IMMUNOTHERAPIESSep 6, 2018LC PATENTS -
STRAWMANSep 5, 2018VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBB -
SCHNAPPAUFSep 4, 2018- -

Patent Citations (40) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1083232
DESCRIPTIONUS4373071
DESCRIPTIONUS4401796
DESCRIPTIONUS4415732
DESCRIPTIONUS4458066
DESCRIPTIONUS4500707
DESCRIPTIONUS4668777
DESCRIPTIONUS4973679
DESCRIPTIONUS5047524
DESCRIPTIONUS5132418
DESCRIPTIONUS5153319
DESCRIPTIONUS5262530
DESCRIPTIONUS5663153
DESCRIPTIONUS5700642
DESCRIPTIONUS6239116
DESCRIPTIONUS6406705
EXAMINATIONEP1685844
EXAMINATIONWO03028656
OPPOSITIONEP1083232
OPPOSITIONEP2216028
OPPOSITIONUS2002064515
OPPOSITIONUS5723335
OPPOSITIONUS6406705
OPPOSITIONWO0102007
OPPOSITIONWO0104313
OPPOSITIONWO02061113
OPPOSITIONWO02098443
OPPOSITIONWO03051401
OPPOSITIONWO03086280
OPPOSITIONWO2004004743
OPPOSITIONWO9855495
OPPOSITIONWO9914346
OTHERWO0193902
OTHERWO03086280
OTHERWO2010037539
SEARCHEP0839912
SEARCHUS5965720
SEARCHUS6322967
SEARCHWO0193902
SEARCHWO0200694

Non-Patent Literature (NPL) Citations (53) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AKASHI, CURR. OPIN. GENET. DEV., (2001), vol. 11, no. 6, pages 660 - 666-
DESCRIPTION- BENNER, FEBS LETT., (1988), vol. 232, pages 225 - 228-
DESCRIPTION- BINDER ET AL., EMBO J., (1994), vol. 13, pages 1969 - 1980-
DESCRIPTION- BROWN ET AL., CELL, (1992), vol. 71, pages 527 - 542-
DESCRIPTION- CAPUT ET AL., PROC. NAD. ACAD. SCI, (1986), vol. 83, pages 1670 - 1674-
DESCRIPTION- DERES ET AL., NATURE, (1989), vol. 342, pages 561 - 564-
DESCRIPTION- ELBASHIR, NATURE, (2001), vol. 411, pages 494 - 498-
DESCRIPTION- GILKESON ET AL., J. CLIN. INVEST, (1995), vol. 95, pages 1398 - 1402-
DESCRIPTION- HELLERIN; PARKER, ANN. REV. GENET., (1999), vol. 33, pages 229 - 260-
DESCRIPTION- HOLCIK ET AL., PROC. NATL. ACAD. SEI. USA, (1997), vol. 94, page 2410-
DESCRIPTION- KAISHO ET AL., TRENDS IMMUNOL, (2001), vol. 22, no. 2, pages 78 - 83-
DESCRIPTION- KOZAK, GENE EXPR., (1991), vol. 1, no. 2, pages 117 - 125-
DESCRIPTION- LIU ET AL., GENOMICS, (1997), vol. 39, pages 171 - 184-
DESCRIPTION- MONTHEITH ET AL., ANTICANCER DRUG RES., (1997), vol. 12, no. 5, pages 421 - 432-
DESCRIPTION- RIEDL ET AL., J. IMMUNOL., (2002), vol. 168, no. 10, pages 4951 - 4959-
OPPOSITION- DRUMMOND et al., "The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes", Nucleic Acids Res., (19850000), vol. 13, no. 20, pages 7375 - 7394, XP055244475-
OPPOSITION- KRIEG, A Laboratory Guide to RNA: Isolation Analysis, and Synthesis, (19960000), pages 145 - 148, XP055273759-
OPPOSITION- KUMAR, Molecular Biology, (20000000), pages 169 - 172, XP055273757-
OPPOSITION- NI et al., "Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-a Secretion and Signaling through a Nucleotide Receptor", J. Biol. Chem., (20020000), vol. 277, no. 15, pages 12689 - 12696, XP055273731-
OPPOSITION- RIEDL et al., "Priming Th1 Immunity to Viral Core Particles is Facilitated by Trace Amounts of RNA Bound to Its Arginine-Rich Domain", J. Immunol., (20020000), vol. 168, pages 4951 - 4959, XP002354381-
OPPOSITION- WEISSMAN et al., "HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response", J. Immunol., (20000000), vol. 165, pages 4710 - 4717, XP008051732-
OPPOSITION- YAMASHITA et al., "Enhancing Activity of Synthetic Polynucleotides on the Induction of Anti-Hapten Antibody Response", I mmunology, (19740000), vol. 26, pages 925 - 936, XP055244468-
OPPOSITION- HOERR et al., "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies", Eur. J. Immunol., (20000000), vol. 30, pages 1 - 7, XP002243972
OPPOSITION- FELGNER et al., "Cationic Lipid-Mediated Delivery of Polynucleotides", METHODS: A Companion to Methods in Enzymology, (19930000), vol. 5, pages 67 - 75, XP000602973
OPPOSITION- AMOS et al., "Influence of Bacterial Ribonucleic Acid on Animal Cells in Culture", Experimental Cell Research, (19630000), vol. 32, pages 14 - 25, XP024858975
OPPOSITION- KARIKO et al., "Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA", Immunity, (20050000), vol. 23, pages 165 - 175, XP002634064
OPPOSITION- KARIKO et al., "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA", Immunity, (2005080), vol. 23, pages 165 - 175, XP008104240
OPPOSITION- SCHUBERTH-WAGNER et al., "A Conserved Histidine in the RNA sensor RIG-I Controls Immune Tolerance to Ni-2'O-Methylated Self RNA", Immunity, (20150000), vol. 43, pages 41 - 51, XP055517711
OPPOSITION- COX et al., "Adjuvants--a classification and review of their modes of action", Vaccine, (19970000), vol. 15, no. 3, pages 248 - 256, XP002201096
OPPOSITION- CELLA et al., "Origin, maturation and antigen presenting function of dendritic cells", Curr. Opin. Immunol., (19970000), vol. 9, pages 10 - 16, XP002166451
OPPOSITION- YING et al., "Cancer therapy using a self-replicating RNA vaccine", Nature Medicine, (19990000), vol. 5, no. 7, pages 823 - 827, XP002222898
OPPOSITION- RESTIFO et al., "The promise of nucleic acid vaccines", Gene Therapy, (20000000), vol. 7, pages 89 - 92, XP055517688
OPPOSITION- ZHOU et al., "RNA Melanoma Vaccine: Induction of Antitumor Immunity by Human Glycoprotein 100 mRNA Immunization", Human Gene Therapy, (19990000), vol. 10, pages 2719 - 2724, XP002660042
OPPOSITION- UEDA et al., "Phosphorothioate-containing RNAs show mRNA activity in the prokaryotic systems in vitro", Nucleic Acids Res., (19910211), vol. 19, no. 3, pages 547 - 552, XP001536634
OPPOSITION- UEDA et al., "Phosphorothioate-containing RNAs show mRNA activity in the prokaryotic translation systems in vitro", Nucleic Acids Res., (19910000), vol. 19, no. 3, pages 547 - 552, XP001536634
OPPOSITION- LEWIS et al., "The role of the cap structure in RNA processing and nuclear export", Eur. J. Biochem., (19970000), vol. 247, pages 461 - 469, XP055273736
OPPOSITION- STEIN, "The experimental use of antisense oligonucleotides: a guide for the perplexed", J. Clin. Invest., (20010000), vol. 108, no. 5, pages 641 - 644, XP002986037
OTHER- ALBERTS et al., Book: Molecular Biology of the Cell, (19890000), page 214-
OTHER- DRUMMOND et al., "The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes.", Nucleic Acids Research, (19850000), vol. 13, no. 20, pages 7375 - 7394, XP055244475-
OTHER- YAMASHITA et al., "Enhancing activity of synthetic polynucleotides on the induction of anti-hapten antibody", Immunology, (19740000), vol. 26, pages 925 - 936, XP055244468-
OTHER- PILCH et al., "Preliminary studies of specific immunotherapy of cancer with immune RNA", Cancer, (19770000), vol. 40, pages 2747 - 2757, XP055244434
OTHER- HOERR et al., "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.", Eur. J. Immunol, (20000830), vol. 30, pages 1 - 7, XP002243972
OTHER- SAENZ et al., "RNA as a tumor vaccine: a review of the literature", Exp. Dermatol, (20011221), vol. 10, pages 143 - 154, XP055244457
OTHER- GREENUP et al., Br. J. Cancer, (19780000), vol. 38, pages 55 - 63, XP055244456
OTHER- GANTHIER et al., "TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages", J. Immunol., (20080215), vol. 180, no. 4, pages 2117 - 2124, XP055025782
OTHER- FORSBACH et al., "Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses", J. Immunol, (20080315), vol. 180, no. 6, pages 3729 - 3738, XP055244494
OTHER- NALLAGATLA et al., "A brilliant disguise for self RNA: 5'-end and internal modifications of primary transcripts suppress elements of innate immunity", RNA Biology, (20080701), vol. 5, no. 3, pages 140 - 144, XP055112032
SEARCH- ARA Y ET AL, "Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system.", IMMUNOLOGY MAY 2001 LNKD- PUBMED:11380697, (200105), vol. 103, no. 1, ISSN 0019-2805, pages 98 - 105, XP002609534 [Y] 1-16 * the whole document *-
SEARCH- HEIDENREICH O ET AL, "CHEMICALLY MODIFIED RNA: APPROACHES AND APPLICATIONS", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, (1993), vol. 7, no. 1, ISSN 0892-6638, pages 90 - 96, XP002043382 [Y] 1-16 * the whole document *-
SEARCH- HEYMAN ET AL, "The immune complex: possible ways of regulating the antibody response", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 11, doi:10.1016/0167-5699(90)90126-T, ISSN 0167-5699, (19900101), pages 310 - 313, (19900101), XP026942265 [Y] 1-16 * the whole document *
SEARCH- AGRAWAL S, "Antisense oligonucleotides: towards clinical trials", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (19961001), vol. 14, no. 10, ISSN 0167-7799, pages 376 - 387, XP004035728 [X] 1-5,8 * page 377, column L, paragraph 4 - page 379, column L, paragraph 1; table 1 * [Y] 6,7,9,11-16 [I] 10
SEARCH- GRYAZNOV S M, "Oligonucleotide N3'->P5' phosphoramidates as potential therapeutic agents", BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, (19991210), vol. 1489, no. 1, ISSN 0167-4781, pages 131 - 140, XP004275528 [Y] 1-16 * page 135, column R, paragraph 3 * * page 132, column R, paragraph 3 - page 133, column L, paragraph 1 * * abstract *
SEARCH- MATRAY T J GRYAZNOV S M, "Synthesis and properties of RNA analogs - oligoribonucleotides N3' - p5' phosphoramidites", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, (1999), vol. 27, no. 20, ISSN 0305-1048, pages 3976 - 3985, XP002955971 [Y] 1-16 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents